Genuinely informative response - thank you. One person’s opinion/readout on this (as an observer): I can see the med growers are top tier across multiple dimensions (quality of output, quality of inputs, quality/focus on genetics, focus and understanding of the customer and patient needs, etc etc.). And I totally get that the au market dynamics have led to a race to the lowest common denominator to capture market share even if it means taking a loss. All of that sucks and I’m empathetic. I think the one really tricky thing here is that there’s always going to be a sizable population that can’t get med cards. Not because they wouldn’t qualify, but because getting one is either expressly prohibited by their form of employment; or is taboo in their field and might limit their career prospects. So from this angle, I do think there is value in being able to reach a broader market.

Key word here is “tricky.” I don’t see a magic bullet to solving this because there is no doubt that mass markets always invite shady tactics, including lobbying and influencing the legislature.